GLORIA-AF Registry Program (Phase I)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01428765 |
Recruitment Status
:
Completed
First Posted
: September 5, 2011
Results First Posted
: March 5, 2014
Last Update Posted
: March 5, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Atrial Fibrillation |
Study Design:
cross-sectional
Study Type : | Observational |
Actual Enrollment : | 1096 participants |
Time Perspective: | Cross-Sectional |
Official Title: | GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase I) |
Study Start Date : | May 2011 |
Actual Primary Completion Date : | January 2013 |
Actual Study Completion Date : | January 2013 |

- CHADS2 Score [ Time Frame: Baseline ]CHADS2 score is based on a point system in which 2 points are assigned for a history of stroke or transient ischemic attack and 1 point each is assigned for age equal to or greater more than 75 years, hypertension, diabetes, or clinical heart failure or impaired left ventricular systolic function (generally interpreted as an ejection fraction ≤ 40%).
- CHA2DS2-VASc Score [ Time Frame: Baseline ]The CHA2DS2-VASc risk score is based on a point system in which 2 points are assigned for a history of stroke or TIA, or age ≥75; and 1 point each is assigned for age 65-74 years, a hypertension, diabetes, cardiac failure, vascular disease and female sex. On the basis of the risk strata defined in previous guidelines, a CHA2DS2-VASc score of 0 corresponds to "low risk", a score of 1 corresponds to "intermediate risk", and a score of 2 or more corresponds to "high risk".
- HAS-BLED Risk Score [ Time Frame: Baseline ]The HAS-BLED score is based on a point system in which 1 point is assigned for hypertension (systolic blood pressure >160 mmHg), 1 point for each of abnormal renal (presence of chronic dialysis or renal transplantation or serum creatinine ≥200 μmol/L) and liver (chronic hepatic disease or biochemical evidence of significant hepatic derangement) function, 1 point each is assigned for stroke, bleeding (previous bleeding history and/or predisposition to bleeding), labile Internation Normalized Ratios (INRs,unstable/high INRs or poor time in therapeutic range), age >65 years and 1 point each for drugs (such as antiplatelet agents, non-steroidal anti-inflammatory drugs) or alcohol.
- Antithrombotic Treatment Choice at Baseline [ Time Frame: Baseline ]
- Gender [ Time Frame: Baseline ]
- Age Group [ Time Frame: Baseline ]
- Medical History [ Time Frame: Baseline ]
- Concomitant Medication [ Time Frame: Baseline ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion criteria:
1) Patients newly diagnosed with non-valvular atrial fibrillation at risk for stroke.
Exclusion criteria:
- Presence of any mechanical heart valve, or valve disease that is expected to require valve replacement intervention;
- Patients who have received more than 60 days of oral anticoagulant treatment (vitamin K antagonist) (VKA) in their lifetime;
- Atrial fibrillation (AF) with a generally reversible cause;
- Patients with a medical condition other than atrial fibrillation for which chronic use of an oral anticoagulant (VKAs) is indicated

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01428765

China | |
1160.114.08017 Boehringer Ingelheim Investigational Site | |
Beijing, China | |
1160.114.08018 Boehringer Ingelheim Investigational Site | |
Beijing, China | |
1160.114.08019 Boehringer Ingelheim Investigational Site | |
Beijing, China | |
1160.114.08020 Boehringer Ingelheim Investigational Site | |
Beijing, China | |
1160.114.08023 Boehringer Ingelheim Investigational Site | |
Beijing, China | |
1160.114.08024 Boehringer Ingelheim Investigational Site | |
Beijing, China | |
1160.114.08025 Boehringer Ingelheim Investigational Site | |
Beijing, China | |
1160.114.08007 Boehringer Ingelheim Investigational Site | |
Changsha, China | |
1160.114.08021 Boehringer Ingelheim Investigational Site | |
Dalian, China | |
1160.114.08004 Boehringer Ingelheim Investigational Site | |
Ghuangzhou, China | |
1160.114.08006 Boehringer Ingelheim Investigational Site | |
Ghuangzhou, China | |
1160.114.08001 Boehringer Ingelheim Investigational Site | |
Guangzhou, China | |
1160.114.08002 Boehringer Ingelheim Investigational Site | |
Guangzhou, China | |
1160.114.08005 Boehringer Ingelheim Investigational Site | |
Guangzhou, China | |
1160.114.08011 Boehringer Ingelheim Investigational Site | |
Hangzhou, China | |
1160.114.08015 Boehringer Ingelheim Investigational Site | |
Hangzhou, China | |
1160.114.08026 Boehringer Ingelheim Investigational Site | |
Nanjing, China | |
1160.114.08010 Boehringer Ingelheim Investigational Site | |
Shanghai, China | |
1160.114.08012 Boehringer Ingelheim Investigational Site | |
Shanghai, China | |
1160.114.08014 Boehringer Ingelheim Investigational Site | |
Shanghai, China | |
1160.114.08016 Boehringer Ingelheim Investigational Site | |
Shanghai, China | |
1160.114.08027 Boehringer Ingelheim Investigational Site | |
Shanghai, China | |
1160.114.08028 Boehringer Ingelheim Investigational Site | |
Shenzhen, China | |
1160.114.08022 Boehringer Ingelheim Investigational Site | |
Tianjin, China | |
1160.114.08008 Boehringer Ingelheim Investigational Site | |
Wuhan, China | |
Croatia | |
1160.114.04002 Boehringer Ingelheim Investigational Site | |
Krapinske Toplice, Croatia | |
1160.114.04001 Boehringer Ingelheim Investigational Site | |
Opatija, Croatia | |
1160.114.04003 Boehringer Ingelheim Investigational Site | |
Zagreb, Croatia | |
1160.114.04004 Boehringer Ingelheim Investigational Site | |
Zagreb, Croatia | |
Egypt | |
1160.114.28001 Boehringer Ingelheim Investigational Site | |
Cairo, Egypt | |
Germany | |
1160.114.490201 Boehringer Ingelheim Investigational Site | |
Berlin, Germany | |
1160.114.490216 Boehringer Ingelheim Investigational Site | |
Berlin, Germany | |
1160.114.490220 Boehringer Ingelheim Investigational Site | |
Berlin, Germany | |
1160.114.490217 Boehringer Ingelheim Investigational Site | |
Dessau-Roßlau, Germany | |
1160.114.490214 Boehringer Ingelheim Investigational Site | |
Dinslaken, Germany | |
1160.114.490215 Boehringer Ingelheim Investigational Site | |
Halle, Germany | |
1160.114.490206 Boehringer Ingelheim Investigational Site | |
Itzehoe, Germany | |
1160.114.490209 Boehringer Ingelheim Investigational Site | |
Kempen, Germany | |
1160.114.490208 Boehringer Ingelheim Investigational Site | |
Ludwigsburg, Germany | |
1160.114.490212 Boehringer Ingelheim Investigational Site | |
Markkleeberg, Germany | |
1160.114.490207 Boehringer Ingelheim Investigational Site | |
Mühldorf, Germany | |
1160.114.490210 Boehringer Ingelheim Investigational Site | |
München, Germany | |
1160.114.490202 Boehringer Ingelheim Investigational Site | |
Northeim, Germany | |
1160.114.490204 Boehringer Ingelheim Investigational Site | |
Nürnberg, Germany | |
1160.114.490211 Boehringer Ingelheim Investigational Site | |
Wittenberg, Germany | |
Lebanon | |
1160.114.07001 Boehringer Ingelheim Investigational Site | |
Beirut, Lebanon | |
Netherlands | |
1160.114.31013 Boehringer Ingelheim Investigational Site | |
Deventer, Netherlands | |
1160.114.31008 Boehringer Ingelheim Investigational Site | |
Enschede, Netherlands | |
1160.114.31005 Boehringer Ingelheim Investigational Site | |
Maastricht, Netherlands | |
Spain | |
1160.114.34012 Boehringer Ingelheim Investigational Site | |
Barcelona, Spain | |
1160.114.34004 Boehringer Ingelheim Investigational Site | |
Jaén, Spain | |
1160.114.34010 Boehringer Ingelheim Investigational Site | |
Madrid, Spain | |
1160.114.34005 Boehringer Ingelheim Investigational Site | |
Murcia, Spain | |
1160.114.34003 Boehringer Ingelheim Investigational Site | |
Málaga, Spain | |
1160.114.34013 Boehringer Ingelheim Investigational Site | |
Sabadell (Barcelona), Spain | |
1160.114.34011 Boehringer Ingelheim Investigational Site | |
Santiago de Compostela, Spain | |
1160.114.34001 Boehringer Ingelheim Investigational Site | |
Sevilla, Spain | |
1160.114.34006 Boehringer Ingelheim Investigational Site | |
Sevilla, Spain | |
Turkey | |
1160.114.09004 Boehringer Ingelheim Investigational Site | |
Adana, Turkey | |
1160.114.09001 Boehringer Ingelheim Investigational Site | |
Ankara, Turkey | |
1160.114.09006 Boehringer Ingelheim Investigational Site | |
Antalya, Turkey | |
1160.114.09009 Boehringer Ingelheim Investigational Site | |
Istanbul, Turkey |
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Boehringer Ingelheim |
ClinicalTrials.gov Identifier: | NCT01428765 History of Changes |
Other Study ID Numbers: |
1160.114 |
First Posted: | September 5, 2011 Key Record Dates |
Results First Posted: | March 5, 2014 |
Last Update Posted: | March 5, 2014 |
Last Verified: | January 2014 |
Additional relevant MeSH terms:
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |